Representative traces from whole-cell patch clamp recordings taken from Left: hM3D-positive neuron and Right: hM4D-positive neuron in response to bath application of CNO (1 µM). (b) The effect of CNO on membrane potential in individual Left: hM3D-positive neurons (n=10, paired-samples t-test, ***P <0.001) and Middle: hM4D-positive neurons (n=20, paired-samples t-test, **P < 0.01). Right: CNOinduced change in membrane potential from baseline recorded in hM3D-and hM4D-positive neurons. CNO depolarized hM3D-expressing neurons and hyperpolarized hM4D-expressing neurons. (c) Left: Representative traces of evoked action potentials taken from Top: hM3D-and Bottom: hM4D-positive neurons under the 100 pA and 300 pA stimulus. Right: Relationship between the number of evoked action potentials and current injection (from 100 pA to 300 pA) in Top: hM3D-and Bottom: hM4D-positive neurons. CNO increased evoked action potential firing in hM3D-positive neurons (n=8, R 2 =0.9313 for aCSF, R 2 =0.9409 for CNO, two-away ANOVA, ***P<0.001) and suppressed evoked action potential firing in hM4D-positive neurons (n=14, R 2 =0.9521 for aCSF, R 2 =0.9723 for CNO, two-away ANOVA, ***P<0.001).
Supplementary Figure 2.
hM4D-mediated inhibition of mAON activity has no effect on the novelty response to odours or locomotor activity. (a) CNO did not alter habituation to novel odours (n=10, twoway ANOVAs, all interactions F (2,18) <2.70, ns, P>0.095; all main effects of trial F (2,18) >10.26, P<0.01) or the reinstatement of novel odour investigation (all interactions F (1,9) <2.81, ns, all main effects of trial F (1,9) >26.68, P<0.01). (b) Open field locomotor activity was unaltered following CNO treatment (n=10, paired-samples t-test, t(9)=1.67, ns, P=0.13).
Supplementary Figure 3.
Systemic injection of CNO has no effect on olfactory-dependent behaviours and locomotor activity in a sham surgery control group. For sham surgery control, a separate group of mice were prepared that underwent the same surgical procedures as mice in the hM3D or hM4D conditions, but did not express the transgenes in the AON. (a) CNO treatment did not influence the latency to locate a buried food reward in sham surgery animals (n=9, paired-samples t-test, t (8) =0.56, ns, P=0.59). (b) Left: CNO-treated mice displayed no change in sociability (vehicle group n=5, CNO group n=5, independent-samples t-test, t (8) =1.049, ns, P=0.32). Right: CNO-treated mice were able to distinguish between a novel and familiar conspecific (independent-samples t-test, t (8) =0.90, ns, P=0.39). (c) CNO did not alter habituation to novel odours or the reinstatement of novel odour investigation (n=9, two-way ANOVAs, all interactions F(14, 120)<3.40, ns, P=0.36; all main effects of trial F(14, 120)>12.88, P<0.001). (d) Open field locomotor activity was unaffected by CNO treatment (n=11, paired-samples t-test, t (10) =0.1364, ns, P=0.89).
Supplementary Figure 4.
hM3D-mediated activation of mAON activity has no effect on the novelty response to odours or locomotor activity. (a) CNO did not alter habituation to novel odours (n=10, twoway ANOVAs, all interactions F (2,18) <2.03, ns, P>0.16; all main effects of trial F (2,18) >9.48, P<0.01) or the reinstatement of novel odour investigation (all interactions F (1,9) <1.51, ns, all main effects of trial F (1,9) >29.44, P<0.001). (b) Open field locomotor activity was unaltered following CNO treatment (n=10, paired-samples t-test, t (9) =0.68, ns, P=0.51).
